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noted that increased use of this type of medication represents a
target for quality improvement. The observation that most clini-
cians were not implanting recommendations from published
guidelines is important, but conclusions regarding specific use of
GP IIb/IIIa inhibitors are limited by the fact that the guidelines
referenced in this study have already been superseded by new
guidelines published in 2002 (3), which incorporate research
showing the importance of adding clopidogrel to aspirin early in
the treatment of acute coronary syndromes (4).
The role of GP IIb/IIIa inhibitors for treatment of acute
coronary syndromes at this time is not clear. Therapy with
clopidogrel has not been compared directly to therapy with GP
IIb/IIIa inhibitors, and further data need to be obtained to
determine the incremental value for adding GP IIb/IIIa inhibitors
to aspirin/clopidogrel/heparin therapy (5). Recommendations may
differ in patients with different prognostic risk (as assessed by
clinical/laboratory variables at time of initial presentation) and
whether an interventional or noninterventional approach is being
used. In many cases, GP IIb/IIIa inhibitors may be a fourth
element of antiplatelet/antithrombotic therapy to consider in
patients with acute coronary syndromes.
Neil L. Coplan, MD, FACC
Division of Cardiovascular Medicine
Lenox Hill Hospital
100 E. 77th St.
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REPLY
Dr. Coplan questions the evidence supporting glycoprotein (GP)
IIb/IIIa inhibitors in the care of non–ST-elevation acute coronary
syndrome (ACS). This doubt is remarkable given that GP IIb/IIIa
agents have received more intensive investigation than nearly any
other ACS treatment. More than 30,000 patients have been
studied in six randomized trials of GP IIb/IIIa inhibitors. Three
meta-analyses have summarized the trial results, each concluding
that early use of GP IIb/IIIa agents resulted in a highly significant
overall reduction in risk for death or myocardial infarction (1–3).
Dr. Coplan is correct that the benefits tended to be greater in those
patients with higher risk (as marked by positive cardiac markers,
ST depression, or patients selected for interventional procedures,
or those with other high-risk clinical features such as diabetes
mellitus, heart failure, or advanced age). These findings are similar
to those seen for many ACS interventions and argue for appro-
priate risk-based treatment strategies. Based on these findings,
both the 2000 American College of Cardiology/American Heart
Association Guidelines and the current 2002 Guidelines Update
recommend the use of GP IIb/IIIa inhibitors in high-risk ACS
patients (4,5). To this body of knowledge, our current study
provided further confirmatory evidence that early use of GP
IIb/IIIa inhibitors was associated with significantly lower in-
hospital mortality rates when used in a community-based non–
ST-elevation patient population. These benefits were also seen in
all patient subgroups including those receiving conservative, non-
interventional care (6).
Dr. Coplan is correct that there are limited randomized trial
data on the incremental value of other antiplatelet therapies (such
as clopidogrel) in patients already receiving a GP IIb/IIIa agent or
vice versa. However, in the absence of data, one cannot conclude
which agent is superior and/or whether a combined approach may
yield the best results. Specifically, use of intravenous (IV) GP
IIb/IIIa inhibitors results in much more rapid and complete
inhibition of platelet aggregation than an oral inhibitor such as
clopidogrel. Yet clopidogrel can be continued after IV GP IIb/IIIa
agents have been discontinued and still provide long-term benefits
(in combination with aspirin) in patients with coronary disease (7).
Whether first, second, third, or “fourth,” we would hope that
clinicians would use all guidelines-indicated therapies to improve
the outcomes of patients with ACS.
Eric David Peterson, MD, MPH, FACC
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“From Bedside to Bench”
I read with interest the study by Hasegawa et al. (1) that
demonstrated elegantly the relationship among mitral annular
movement, the increase in left ventricular radial dimensions, and
filling in dogs. In normal conditions the left ventricle increases
across its three dimensions in close relationship with the time of
early filling. With severe heart failure and increase in left atrial
pressures and left atrial–left ventricular pressure gradient, this
relationship remains maintained only across the radial dimensions
but is lost along the long axis, which becomes delayed by 37 ms.
Furthermore, in contrast to the radial axis, the increase in long-axis
dimension correlates negatively with the progressive increase in left
atrial–left ventricular pressure gradient.
This interesting study confirms what has previously been
demonstrated in patients with severe heart failure and restrictive
left ventricular filling (2). Though the minor axis increases early,
the mitral valve opens at the same time the aortic valve closes,
making isovolumic relaxation time zero. Even Doppler isovolumic
relaxation time is very short. Interestingly, long-axis shortening
remains until the early diastolic left atrial–left ventricular pressure
gradient starts to decline, in contrast to normals in whom long-axis
lengthening occurs before the onset of filling. This disturbed
pattern reverses to the slow relaxation one with successful unload-
ing of the left atrium by angiotensin-converting enzyme (ACE)
inhibitors, resulting in long isovolumic relaxation time and inco-
ordinate long-axis shortening despite no significant change in
radial axis toward the left ventricle (3). This significant change in
left ventricular physiology with ACE inhibitors coincides with
improvement of symptoms.
The investigators (1) state that early diastolic mitral annular
movement occurred while left ventricular pressure was higher or
equal to left atrial pressure. If that really was the case, blood flow
should have ceased completely in early diastole rather than becom-
ing the main filling component of the ventricle. The slow and
delayed lengthening of the long axis may, therefore, represent an
ischemic subendocardial behavior (long axis) that has previously
been shown in patients with coronary artery disease as a conse-
quence of the raised left atrial pressure. Accepting this as a possible
interpretation of the delayed long-axis relaxation in this setting
may explain the known poor prognosis in patients with heart
failure and restrictive filling pattern, in whom the ischemic
subendocardium may be the substrate for fatal arrhythmia.
Michael Henein, MD, PhD, FACC
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REPLY
We are grateful for Drs. Henein and O’Callaghan’s interest in our
study (1). Although we agree that ischemia may contribute to
impaired long-axis lengthening and a restricted left ventricular
(LV) filling pattern in some patients, these abnormalities can occur
in the absence of ischemia.
Drs. Henein and O’Callaghan repeat the common misconcep-
tion that early rapid left ventricular filling ceases when LV pressure
equals left atrial pressure. Early diastolic LV filling results from the
acceleration of blood from the left atrium to the left ventricle (LV)
in response to a pressure gradient (2). As LV relaxation slows, the
ventricle fills, and the left atrium empties; the pressure gradient is
reduced and then abolished. When LV and left atrial pressures are
equal, there is no longer a pressure gradient to accelerate blood into
the LV, so the rate of LV filling stops increasing. After this time,
LV pressure exceeds left atrial pressure, and this decelerates and
eventually stops LV filling (3). Thus, the peak rate of LV filling
occurs coincidentally with equalization of left atrial and LV
pressures (see Fig. 3 of our report [1]).
We found that under normal conditions, peak LV filling and
LV long-axis lengthening occurs simultaneously and is coincident
with the equalization of LA and LV pressures. With impaired
relaxation, the long-axis lengthening of the ventricle is delayed and
occurs after crossover of left atrial to LV pressure and, thus, is
much less sensitive to left atrial pressure. This explains why the
peak rate of long-axis lengthening (EM) is reduced in patients with
slow LV relaxation, even if left atrial pressure is markedly elevated.
William C. Little, MD, FACC
Section on Cardiology
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